Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer Journal Article
| Authors: | Mai, N.; Chen, J. F.; Rana, S.; Robson, M.; Chandarlapaty, S.; Rosen, E. Y. |
| Article Title: | Pathologic complete response to KEYNOTE522 and HER2-directed therapy for synchronous TNBC and HER2+ breast cancer |
| Abstract: | Simultaneous presentation of two separate primary breast cancers of differing histology at initial diagnosis is an uncommon phenomenon; it is even rarer to find these pathologically distinct populations within the same biopsy. Here we report the case of a patient diagnosed with clearly demarcated, pathologically heterogenous triple negative breast cancer (TNBC) and HER2+ breast cancer that was treated with a hybrid chemoimmunotherapy regimen combining elements of Keynote-522 and a standard HER2-directed neoadjuvant regimen, yielding apathologic complete response by the time of surgery with no notable adverse events. Molecular analysis of the histologically distinct tumor populations confirmed molecular evidence of differential HER2 expression but also suggested clonal relatedness of the two tumor populations based upon mutational profile, with phenotypic divergence potentially resulting from copy number alterations in NF1. Overall, this case highlights a rare histologic phenomenon that was successfully treated by combining both TNBC and HER2 directed neoadjuvant therapies. © The Author(s) 2024. |
| Keywords: | immunohistochemistry; adult; clinical article; human tissue; somatic mutation; case report; doxorubicin; paclitaxel; neoadjuvant therapy; follow up; carboplatin; multiple cycle treatment; echomammography; mastectomy; cyclophosphamide; cell population; loading drug dose; in situ hybridization; breast tumor; breast carcinoma; tumor cell; trastuzumab; breast biopsy; pertuzumab; pathological complete response; triple negative breast cancer; chemoimmunotherapy; human epidermal growth factor receptor 2 positive breast cancer; invasive breast cancer; human; female; article; pembrolizumab; ultrasound guided biopsy |
| Journal Title: | npj Precision Oncology |
| Volume: | 8 |
| ISSN: | 2397-768X |
| Publisher: | Springer Nature |
| Date Published: | 2024-07-28 |
| Start Page: | 162 |
| Language: | English |
| DOI: | 10.1038/s41698-024-00631-9 |
| PROVIDER: | scopus |
| PMCID: | PMC11284213 |
| PUBMED: | 39069534 |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work